Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
NCT ID: NCT02914119
Last Updated: 2019-09-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30430 participants
OBSERVATIONAL
2016-10-01
2017-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* the frequency of use of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia
* the incidence of residual neuromuscular blockade, and
* the timing of reversal of the neuromuscular blockade at the end of anaesthesia.
We will collect data from 7 Danish anaesthesia departments, using data from the Anaesthesia Information Management System (AIMS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia
NCT07044193
Qualitative Analysis of Barriers to Consistent Use of Neuromuscular Monitoring in General Anaesthesia
NCT02239965
Residual Neuromuscular Blockade in Pediatric Anesthesia
NCT02939911
A Comparison of Rocuronium 0.6 mg/kg and Remifentanil 2 µg/kg in Elderly Patients Over 80 Years
NCT04287426
Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade
NCT05037006
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eligible patients
Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Jakob Louis Thomsen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jakob Louis Thomsen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jakob L Thomsen, MD
Role: PRINCIPAL_INVESTIGATOR
Sponsor principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herlev Hospital
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JLT-NM4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.